ABBOTT LABORATORIES — Director's Dealing 2019

Nov 20, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-11-11

Reporting Person: DALE MICHAEL D (Senior Vice President)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	25294	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$50.72	2027-07-20	Common shares (17600)		Direct
Option (right to buy)	$59.94	2028-02-15	Common shares (46403)		Direct
Option (right to buy)	$75.90	2029-02-21	Common shares (38190)		Direct

Footnotes

F1: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,867 and 5,866 on July 21, 2018 and July 21, 2019, respectively, and 5,867 becomes exercisable on July 21, 2020.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments, of which 15,468 became exercisable on February 16, 2019 and 15,467 and 15,468 become exercisable on February 16, 2020 and February 16, 2021, respectively.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,730 on February 22, 2020, 12,730 on February 22, 2021, and 12,730 on February 22, 2022.